Literature DB >> 8432955

Concordance between clinical and self-report depression scales during the acute phase and after treatment.

C Senra1, A Polaino.   

Abstract

The concordance between self-report and clinical rating scales of depression increases during progress from the acute depressive episode to recovery or improvement of symptoms. We investigated this convergence in a group of 52 outpatients with DSM-III major depression disorders using three widely employed depression scales and their parallel formats (i.e., alternative modes of administering the scales). The six instruments were applied at admission and after 12 and 24 weeks' treatment. The results indicate that the increase in the global concordance between scales may be a statistical effect deriving from broadening of the range of scores.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8432955     DOI: 10.1016/0165-0327(93)90091-w

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  3 in total

1.  Sensitivity to changes during antidepressant treatment: a comparison of unidimensional subscales of the Inventory of Depressive Symptomatology (IDS-C) and the Hamilton Depression Rating Scale (HAMD) in patients with mild major, minor or subsyndromal depression.

Authors:  Isabella Helmreich; Stefanie Wagner; Roland Mergl; Antje-Kathrin Allgaier; Martin Hautzinger; Verena Henkel; Ulrich Hegerl; André Tadić
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-09-30       Impact factor: 5.270

2.  Validity of the definite and semidefinite questionnaire version of the Hamilton Depression Scale, the Hamilton Subscale and the Melancholia Scale. Part I.

Authors:  Jesper Bent-Hansen; Per Bech
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-03-02       Impact factor: 5.270

3.  Correlation between patient and clinician assessments of depression severity in the PREVENT study.

Authors:  Boadie W Dunlop; Thomas Li; Susan G Kornstein; Edward S Friedman; Anthony J Rothschild; Ron Pedersen; Philip Ninan; Martin Keller
Journal:  Psychiatry Res       Date:  2010-03-21       Impact factor: 3.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.